Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Gastroenterology

Volumn 153, Issue 1, 2017, Pages 113-122

  Jacobson, Ira M ^a,b   Lawitz, Eric ^c   Gane, Edward J ^d   Willems, Bernard E ^e   Ruane, Peter J ^f   Nahass, Ronald G ^g   Borgia, Sergio M ^h   Shafran, Stephen D ⁱ   Workowski, Kimberly A ^j   Pearlman, Brian ^k   Hyland, Robert H ^l   Stamm, Luisa M ^l   Svarovskaia, Evguenia ^l   Dvory Sobol, Hadas ^l   Zhu, Yanni ^l   Subramanian, G Mani ^l   Brainard, Diana M ^l   McHutchison, John G ^l   Bräu, Norbert ^b,m   Berg, Thomas ⁿ   Agarwal, Kosh ^o   Bhandari, Bal Raj ^p   Davis, Mitchell ^q   Feld, Jordan J ^r   Dore, Gregory J ^s,t   Stedman, Catherine A M ^u   Thompson, Alexander J ^v   Asselah, Tarik ^w   Roberts, Stuart K ^x   Foster, Graham R ^y   more..

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Ruane Medical and Liver Health Institute   (United States)

^g ID Care   (United States)

^h University of Queensland   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j EMORY UNIVERSITY   (United States)

^k Department of Pathology Atlanta Veterans Affairs Medical Center   (Georgia)

^l GILEAD SCIENCES   (United States)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o KING S COLLEGE HOSPITAL   (United Kingdom)

^p Gastroenterology and Nutritional Medical Services ^*  (United States)

^q South Florida Center of Gastroenterology   (United States)

^r TORONTO WESTERN HOSPITAL   (Canada)

^s UNIVERSITY OF NEW SOUTH WALES   (Australia)

^t UNIVERSITY OF NEW SOUTH WALES   (Australia)

^u UNIVERSITY OF OTAGO   (New Zealand)

^v ST VINCENT S HOSPITAL   (Australia)

^w BEAUJON HOSPITAL   (France)

^x ALFRED HOSPITAL   (Australia)

^y ROYAL LONDON HOSPITAL   (United Kingdom)

more..

Author keywords

Clinical Trial; Comparison; Direct Acting Antiviral Agent; Shortened Duration Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; HEMOGLOBIN; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VIRUS RNA; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; MACROCYCLIC COMPOUND; SOFOSBUVIR; SULFONAMIDE; VELPATASVIR; VOXILAPREVIR;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHRONIC HEPATITIS C; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPONATREMIA; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NONHUMAN; OPEN STUDY; PELVIS FRACTURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REBOUND; RELAPSE; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; SOFOSBUVIR; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

EID: 85020935632     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.03.047     Document Type: Article

References (27)

1. Carter, W., Connelly, S., Struble, K., Reinventing HCV treatment: past and future perspectives. J Clin Pharmacol 27 (2017), 287–296.
2. Chen, T., Terrault, N., Treatment of chronic hepatitis C in patients with cirrhosis. Curr Opin Gastroenterol 32 (2016), 143–151.
3. Naggie, S., Muir, A.J., Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med 68 (2017), 345–358.
4. Asselah, T., Boyer, N., Saadoun, D., et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36:Suppl S1 (2016), 47–57.
5. Nafisi, S., Roy, S., Gish, R., et al. Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. Expert Rev Anti Infect Ther 14 (2016), 41–56.
6. Majumdar, A., Kitson, M.T., Roberts, S.K., Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 43 (2016), 1276–1292.
7. Feld, J.J., Foster, G.R., Second generation direct-acting antiviral-do we expect major improvements?. J Hepatol 65 (2016), S130–S142.
8. Petersen, T., Townsend, K., Gordon, L.A., et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int 10 (2016), 310–319.
9. Sovaldi (sofosbuvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences, 2014. Available from: http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Accessed December 11, 2016.
10. Harvoni (ledipasvir and sofosbuvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences, 2015. Available from: http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed December 11, 2016.
11. Epclusa (sofosbuvir and velpatasvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences, 2016. Available from: https://www.gilead.com/∼/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf?la=en. Accessed December 11, 2016.
12. Lawitz, E., Freilich, B., Link, J., et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 22 (2015), 1011–1019.
13. Feld, J.J., Jacobson, I.M., Hézode, C., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
14. Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
15. Taylor, J., Appleby, T., Barauskas, O., et al. Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol, 62, 2015, S681.
16. Kirby, B., Yang, J., Yang, C., et al. P0861: evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteers. J Hepatol, 62, 2015, S663.
17. Rodriguez-Torres, M., Glass, S., Hill, J., et al. GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat 23 (2016), 614–622.
18. Gane, E., Schwabe, C., Hyland, R., et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology 151 (2016), 448–456.
19. Lawitz, E., Reau, N., Hinestrosa, F., et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology 15 (2016), 893–901.
20. Gane, E., Kowdley, K., Pound, D., et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with HCV genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology 15 (2016), 902–909.
21. Aghemo, A., Buti, M., Hepatitis C therapy: game over!. Gastreoenterology 151 (2016), 795–798.
22. Kwo, P., Gitlin, N., Nahass, R., et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64 (2016), 370–380.
23. Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64 (2016), 360–369.
24. Lawitz, E., Sulkowski, M.S., Ghalib, R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
25. Reau, N., Nguyen, M.H., Kowdley, K.V., et al. Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies. Hepatology, 63(Suppl), 2016, 415A.
26. Bourliere, M., Gordon, S.C., Flamm, S.L., et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (2017), 2134–2146.
27. Banerjee, D., Reddy, K.R., Safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 43 (2016), 674–696.